KR101810138B1 - Composition comprising tea extract and lactic acid bacteria - Google Patents

Abstract

The present invention discloses a composition for preventing or ameliorating intestinal diseases including tea extract and lactic acid bacteria. And a step of extracting tea fermented with a lactic acid bacterium.

Description

[0001] The present invention relates to a tea extract and a composition containing lactic acid bacteria,

The present invention relates to a composition comprising a tea extract and a lactic acid bacterium.

In general, drinking tea is the deactivation and dehydration of oxidizing enzymes present in camellia sinensis buds or leaves of Camellia sinensis. Tea started drinking from BC to contain polyphenols, caffeine, amino acids, proteins, saponins, vitamins, minerals, and has been known to have an effect of increasing the anti-cancer effect and immunity.

Lactobacillus belongs to probiotics and is known to have beneficial health effects upon ingestion. In order for lactic acid bacteria to work effectively, they should resist resistance to stomach acid and succulent acid, so that they can reach the small intestine and proliferate and settle in the intestine. They should be useful in the intestine and be non-toxic and non-pathogenic. Currently, there are 19 kinds of lactic acid bacteria allowed in health functional food, and 11 kinds of Lactobacillus, 1 kind of Lactococcus, 2 kinds of Enterococcus, 1 kind of Streptococcus, Bifidobacterium (Bifidobacterium) can be divided into four species. It is known that lactic acid bacteria of 10 ⁸ to 10 ¹⁰ CFU / g should be consumed in order to exhibit the effect of proliferation of the intestinal beneficial bacteria, inhibition of harmful bacteria, and smoothness of bowel activity.

The present invention is intended to provide a composition for preventing or ameliorating bowel disease. The present invention also provides a method for effectively producing the composition.

One aspect of the present invention provides a composition for preventing or ameliorating intestinal diseases including tea extract and lactic acid bacteria.

Another aspect of the present invention provides a method for producing the composition comprising extracting tea fermented with lactic acid bacteria.

The composition according to the present invention can prevent or ameliorate intestinal diseases by inhibiting proliferation of cancer cells and activating intestinal immune cells and macrophages by including tea extract and lactic acid bacteria.

The composition according to the present invention can produce a composition containing a lactic acid bacterium and a tea extract more efficiently at a time.

1 is a graph showing the inhibitory effect of a composition containing at least one of catechin and lactic acid bacteria on colorectal cancer cells.
Figure 2 is a graph showing the degree of intestinal immune cell activation of a composition comprising at least one of catechin and lactic acid bacteria.
3 shows the degree of macrophage activation of a composition comprising catechin and a lactobacillus paracase.

In the present specification, the term "tea extract" broadly includes all extracts derived from tea leaves. Specifically, the tea extract is prepared by extracting tea leaves before or after processing, tea leaves, and then adding cold water or ionized water A liquid obtained by concentrating the tea leaf extract, a solid preparation prepared by processing tea leaf extract, and the like. As used herein, the term "tea leaf " refers to shoots or leaves of Camellia sinensis and does not distinguish its quality or type. Specific examples include sprouts and leaves of spring tea, summer tea, autumn tea according to harvesting time, and shoots or leaves of ocher tea which increase the amount of chlorophyll by covering a light-shielding film depending on the application, but are not limited thereto.

In the present specification, "lactic acid bacteria" is generically referred to as bacteria that ferment saccharides to obtain energy and produce a large amount of lactic acid. Typically, lactic acid bacteria include Lactobacillus bacteria (Lactobacillus), Lactococcus (Lactococcus), flow Stock Kono (Leuconostoc), Peddie Oh Caucus (Pediococcus) and Bifidobacterium (Bifidobacterium) spp.

The beneficial effect of tea, such as the anticancer effect and immunity enhancement, is known to be due to the catechins contained therein. Generally, the tea contains about 13 to 30% by weight of catechin relative to the weight of tea. Catechins contained in the tea include epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC) and its structural isomers gallocatechin gallate (GCG) Eight species of catechin (GC), catechin gallate (CG), and catechin (C) are known. Among them, epigallocatechin gallate occupies the largest content of 9 to 13% by weight based on the total weight. The tea extract extracted from the tea with water has an extraction yield of about 15 to 25%, and more than 50% of the catechins contained therein are epigallocatechin gallate or epigallocatechin.

Live lactic acid bacteria, that is, lactic acid bacteria which are live bacteria, are inhibited from activity under normal temperature conditions of air, so they must be stored and circulated in refrigeration or vacuum to exhibit their efficacy. In addition, lactic acid bacteria have low resistance to gastric acid and succinic acid, and after the passage through the stomach, the activity is inhibited so that they can be coated or encapsulated to reach the intestines. On the other hand, it is known that lactic acid bacteria, which are dead bacteria, also activate immune cells to increase immunity and improve the intestinal environment. Lactic acid bacteria, which are dead bacteria, have a long shelf life and are easy to store and have high industrial value compared to live bacteria.

The effects of tea and lactic acid bacteria including catechins, which are beneficial to health, have been extensively studied. However, synergistic effects between lactic acid bacteria and tea extracts and lactic acid bacteria that actively grow in the presence of tea extracts are not known. The present inventors have thus found out the present invention.

One aspect of the present invention provides a composition for preventing or ameliorating intestinal diseases including tea extract and lactic acid bacteria. The composition comprising the tea extract and the lactic acid bacterium has an excellent effect of activating the intestinal immune cells and the macrophage cells, respectively, as compared with the composition containing the tea extract alone, thereby improving the intestinal immune function and preventing or ameliorating intestinal diseases. In addition, particularly, the effect of inhibiting the proliferation of colon cancer cells is excellent, so that colon cancer can be effectively prevented or treated.

In one aspect of the invention, the tea extract comprises catechin. In another aspect of the invention, the catechin comprises at least one of epigallocatechin gallate, epigallocatechin, epicatechin gallate, epicatechin, gallocatechin gallate, gallocatechin, catechin gallate and catechin. More specifically, the catechin comprises at least one of epigallocatechin gallate, epigallocatechin, epicatechin gallate, and epicatechin. In another aspect of the invention, the tea extract may comprise from 5 to 50% by weight, in particular from 10 to 40% by weight, of catechin based on the weight of the tea extract.

The composition according to one aspect of the present invention may comprise from 0.0001% to 90%, especially 0.001% to 80%, more specifically 0.01% to 70% by weight of tea extract, based on the total weight of the composition . When the composition according to one aspect of the present invention contains the tea extract in the above weight percentage, it is not only suitable for exhibiting a synergistic effect of preventing or ameliorating bowel disease and containing lactic acid bacteria, but also satisfying the stability and safety of the composition And it may be appropriate to include the above range in terms of cost effectiveness.

In one aspect of the present invention, the lactic acid bacteria may be dead bacteria. The dead cells are not required to be stored by freezing or vacuum packing, and the distribution and storage thereof are easier than live bacteria, and the processing cost is accordingly lower.

In one aspect of the present invention, lactic acid bacteria which are live bacteria can be physically or chemically treated to produce lactic acid bacteria which are dead bacteria. In another aspect of the present invention, the lactic acid bacteria which are live bacteria can be treated with ultrasonic waves or the live bacteria can be crushed into lactic acid bacteria which are dead bacteria.

In one aspect of the invention, the lactic acid bacteria are selected from the group consisting of Lactobacillus plantarum (Lactobacillus plantarum), Lactobacillus paracasei (Lactobacillus paracasei), Lactobacillus brevis (Lactobacillus brevis), Lactobacillus casei (Lactobacillus sakei), Lactobacillus acidophilus (Lactobacillus acidophilus), Lactobacillus Johnson (Lactobacillus johnsonii), Lactobacillus casei (Lactobacillus gasseri), Lactobacillus subtilis (Lactobacillus ssp . lactis), Lactobacillus lambatus (Lactobacillus rhamnosus), Leuconostoxesteroid (Leuconostoc Mesenteroides), Leucono stokudomesenteroid (Leuconostoc pseudoesenteroides), Leuconosistium (Leuconostoc citreum), Pediococcus pentosaceus (Pediococcus . pentosaceus), Enterococcus pathum (Enterococcus faecium), Streptococcus thermophilus (Streptococcusthermophilus) And Lactococcus lactis subunit lactis (Lactococcus lactis ssp . lactis). ≪ / RTI > In another aspect of the invention, the lactic acid bacteria are selected from the group consisting of Lactobacillus plantarumLactobacillus plantarum) And Lactobacillus paracasei (Lactobacillus paracasei). ≪ / RTI > In another aspect of the present invention, the Lactobacillus plantarum comprises KCCM 11179P or KCCM 11181P. Two of these Lactobacillus plantarum were deposited at the Korean Culture Center of Microorganisms (KCCM) on March 28, 2011 as microorganism deposit numbers KCCM11179P and KCCM11181P, respectively.

Name of depository: Korea Microorganism Conservation Center (Domestic)

Accession number: KCCM11179P

Checked on: 20110328

Name of depository: Korea Microorganism Conservation Center (Domestic)

Accession number: KCCM11181P

Checked on: 20110328

The composition according to one aspect of the present invention may contain lactic acid bacteria in an amount of 0.1% by weight to 20% by weight, specifically 0.1% by weight to 10% by weight, based on the total weight of the composition. A composition according to another aspect of the present invention may comprise 10 ⁵ to 10 ¹³ CFU, particularly 10 ⁶ to 10 ¹⁰ CFU of lactic acid bacteria per g of composition. When the composition according to one aspect of the present invention contains the lactic acid bacterium within the above range, it is not only suitable for exhibiting the synergistic effect of preventing or ameliorating intestinal disease and containing the tea extract, but also satisfying the stability and safety of the composition , And it may be appropriate to include the above range in terms of cost-effectiveness.

The composition according to one aspect of the present invention can prevent, ameliorate, or treat intestinal diseases such as diseases caused by weakening of immunity of intestines, proliferation of cancer cells, excessive proliferation of harmful bacteria in intestines, or decreased proliferation of beneficial bacteria in intestines. Specifically, the composition according to one aspect of the present invention can prevent, ameliorate, or treat intestinal diseases including at least one of colon cancer, enteritis, intestinal ulcer, irritable bowel syndrome, diarrhea and constipation.

One aspect of the present invention provides a food composition comprising tea extract and lactic acid bacteria as an active ingredient. The food composition may be a health food composition.

The formulation of the food composition is not particularly limited, but may be formulated into tablets, pills, soft and hard capsules, granules, drinks, caramels, diet bars, tea bags and the like. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients.

The determination of the dosage of the active ingredient is within the level of those skilled in the art, and its daily dose is, for example, from 0.1 mg / day to 10,000 mg / day for tea extract, more specifically from 50 mg / day to 5000 mg / day And may be 10 ⁵ to 10 ¹³ CFU / day, more specifically, 10 ⁶ to 10 ¹⁰ CFU / day for lactic acid bacteria, but is not limited to the age, health condition, complication And the like.

One aspect of the present invention provides a pharmaceutical composition comprising tea extract and lactic acid bacterium as an active ingredient.

When the composition according to the present invention is applied to medicines, it may be formulated into a solid, semi-solid or liquid form by adding a compatible inorganic or organic carrier. The composition of the present invention can be easily formulated according to the conventional method, and can be easily formulated using surfactants, excipients, coloring agents, spices, stabilizers, preservatives, preservatives, wettability agents, emulsification accelerators, suspending agents, salts for controlling osmotic pressure and / , And other commonly used adjuvants may be used as appropriate.

Examples of the agent for oral administration include tablets, pills, granules, soft and hard capsules, powders, fine granules, powders, solutions, emulsions, syrups and pellets. These formulations may contain, in addition to the active ingredient, a diluent such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine, a lubricant such as silica, talc, stearic acid and its magnesium or calcium salt or polyethylene glycol, (E.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpyrrolidine). Optionally, disintegrating agents such as starch, agar, alginic acid or its sodium salt, absorbing agents, coloring agents, flavoring agents, or sweetening agents. The tablets may be prepared by conventional mixing, granulating or coating methods.

Further, the application amount of the effective ingredient will depend on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the administration route and the judgment of the prescriber. Determination of the amount of application based on these factors is within the level of those skilled in the art.

One aspect of the present invention provides a method for producing the composition comprising extracting tea fermented with lactic acid bacteria. In another aspect of the present invention, the method may include a step of fermenting tea leaves with lactic acid bacteria, followed by extracting with water, or an alcohol such as ethanol. The method according to the present invention can more efficiently and simply prepare the composition according to one aspect of the present invention in comparison with the method of separately preparing tea extract and lactic acid bacteria.

Hereinafter, the constitution and effects of the present invention will be described in more detail with reference to Examples and Experimental Examples. However, these examples and experimental examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited thereto.

[Example 1] Preparation of tea extract

The tea leaves are extracted with purified water, purified with alcohol, concentrated and dried to be suitable for edible use. The prepared tea extract contains 27.0 to 41.0% by weight of epigallocatechin gallate, epigallocatechin, epicatechin gallate and epicatechin, and 5% by weight or less of caffeine, based on the total weight of the tea extract.

[Example 2] Preparation of lactic acid bacteria

Lactic acid bacteria are cultured on an MRS agar plate at -80 ° C stock for 24 hours after passage. The cultured single colonies are inoculated on MRS broth and cultured for 24 hours. 100 쨉 l of the cultured colonies are inoculated again on MRS broth and cultured for 48 hours. The cell is then down for 5 minutes at 5000 rpm and washed three times with tertiary distilled water. And sonicated at a temperature of 4 캜 for 2 hours to prepare pulverized lactic acid bacteria.

[Example 3] Preparation of a composition containing lactic acid bacteria and tea extract

The tea leaves are fermented with lactic acid bacteria, extracted with water and purified to prepare a composition containing lactic acid bacteria and tea extract.

[Experimental Example 1] Evaluation of degree of fermentation of tea extract according to lactic acid bacteria

Place the tea leaves in a 50ml conical tube with about half the tea. Tea leaves: Add 2% glucose solution sterilized to a ratio of 6: 4 glucose solution to the tube. The tubes are inoculated with the lactic acid bacteria prepared in Example 2 at about 10 ⁷ to 10 ⁸ g / g. Put the tube lid in a closed incubator at 37 ℃, and incubate the cells with static. After culturing for 24 hours, dilute 10 times with distilled water and measure the pH. A total of 12 kinds of lactic acid bacteria were tested as described above, and the results are shown in the table below.

no Access route Dependent name pH no Access route Dependent name pH One Accession number KCCM11179P Lactobacillus Florata Room 4.61 2 Accession number KCCM11181P Lactobacillus Florata Room 4.72 3 Acquired from CTCbio Lactobacillus paracasei 4.16 4 Acquired from CTCbio Lactobacillus brevis 5.57 5 Acquired from CTCbio Lactobacillus saccharae 5.48 6 Acquired from CTCbio Ryukono Stokesensteroid 5.50 7 Acquired from CTCbio Lactobacillus acidophilus 5.35 8 Acquired from CTCbio Lactobacillus Johnson 5.53 9 Acquired from CTCbio Pediococcus pentosaceus 5.48 10 Acquired from CTCbio Streptococcus thermophilus 5.53 11 Acquired from CTCbio Lactobacillus lambosus 5.27 12 Acquired from CTCbio Lactobacillus acidophilus 5.62

As can be seen from the above results, when the tea leaves are fermented with Lactobacillus plantarum and Lactobacillus paracasei, the pH is kept low. This means that the lactic acid bacteria were proliferated together with tea leaves to produce lactic acid and the tea leaves were fermented by the lactic acid bacteria. Based on the above results, it can be confirmed that a tea extract containing both lactic acid bacteria and catechin can be obtained by fermenting tea leaves with Lactobacillus plantarum and Lactobacillus paracasei.

[Experimental Example 2] Evaluation of inhibition of proliferation of colon cancer cells

(1) Culture of colon cancer cells

Human colon cancer HT-29 cell line (KCLB 30038) was purchased from Korean Cell Line Bank (KCLB). HT-29 colon cancer cells were adjusted to a concentration of 1 × 10 ⁵ cells / mL, and 200 μl each was dispensed into a 48-well plate. The cells were cultured in a 5% CO ₂ incubator for 24 hours Prepared. At this time, the medium was RPMI1640 medium supplemented with 10% FBS and supplemented with penicillin-streptomycin.

(2) Evaluation of inhibition of proliferation of colon cancer cells

Catechin at a concentration of 1 ppm and catechin at a concentration of 1 ppm and lactic acid bacteria at a concentration of 10 ⁷ , 10 ⁶ and 10 ⁵ CFU / 500 μl prepared as in Example 2 were cultured and cultured in human colon cancer cells, And cultured in an incubator of 5% CO ₂ . Lactobacillus was obtained from L. plantarum 1 (obtained from Amorepacific, Accession No .: KCCM11179P) (hereinafter referred to as "LP 1"), Lactobacillus plantarum (Lactobacillus plantarum, (Hereinafter referred to as " LP 3 "), Lactobacillus plantarum 3 (available from CTCbio) (hereinafter abbreviated as " LP 3 ", available from AmorePacific Co., Ltd., Accession No .: KCCM11181P) L. paracasei (obtained from CTCbio), Lactobacillus acidophilus (obtained from CTCbio), and L. rhamnosus (obtained from Lactobacillus L.) CTCbio) were used. The culture was then removed and the cells were washed twice with PBS. 100 μl of MTT solution was added to each well, followed by incubation for 4 hours. Then, the MTT dilution was carefully removed. 100 μl of DMSO was added to each well, carefully shaken for 15-20 minutes with a shaker, and absorbance was measured at 540 nm using an ELISA reader.

 (3) Results

MTT (3- [4,5-dimethylthiazol-2-y1] -2,5-diphenyltetrazolium bromide) is reduced by the action of oxidation-reduction enzymes present in the mitochondrial inner membrane of living cells, producing purple insoluble formazan ). Therefore, the living cell count can be measured by measuring the degree of color development of MTT by absorbance. The number of cells measured in the above is shown in Fig. The test results shown in Fig. 1 show that the concentration of lactic acid bacteria was 10 ⁵ CFU / 500 μl.

 In the case of treatment with only lactic acid bacteria, it can be confirmed that Lactobacillus plantarum 1 (LP 1) and Lactobacillus paracase inhibit the proliferation of colon cancer cells significantly. In the left graph of FIG. 1, Lactobacillus plantarum 1 (LP 1) and Lactobacillus paracase inhibit the growth of colorectal cancer cells by 33% and 23%, respectively.

When lactic acid bacteria and catechin are treated together, it can be confirmed that Lactobacillus paracase inhibits the proliferation of colon cancer cells most significantly. Lactobacillus paracase inhibited the proliferation of colorectal cancer cells by about 19% as compared with the treatment alone. These results show that synergistic effects are obtained in inhibiting the proliferation of colon cancer cells when the lactic acid bacteria and catechin are used together.

[Experimental Example 3] Evaluation of intestinal immune activity

A C3H / HeJ female mouse at 6 to 7 weeks of age is adapted to the surrounding environment for about one week, and mice having good health are selected and used in the experiment. The animals are sacrificed by cervical dislocations, and aseptically the small intestine is removed and only the Peyer's patch is removed from the small intestine. The Feyer's plate is washed with RPMI 1640 medium (Lonza) and pulverized twice using 100 mm Desh to extract the immune cells. The extracted intestinal immune cells are centrifuged at 300 rpm for 10 minutes. The immune cells are suspended in 10% FBS-RPMI 1640 at 5 × 10 ⁶ cells / ml, and 90 μl / well in a 96-well plate.

10 [mu] l of catechin at a concentration of 1 ppm, catechin at a concentration of 1 ppm and lactic acid bacteria at a concentration of 10 ⁷ , 10 ^6, and 10 ⁵ CFU / 500 μl prepared as in Example 2 were each treated with LPS Is treated at a concentration of 10 ug / ml. LP 1, LP 2, LP 3, Lactobacillus paracase, and Lactobacillus lambosus used in Experimental Example 2 are used as the lactic acid bacteria. The treated cells are cultured in a 5% CO ₂ incubator at 37 ° C for 72 hours. 10 μl of CCK-8 (Cell counting kit-8) system (Dojindo, Japan) was treated 3 hours before the end of cell culture and then cultured in a 5% CO ₂ incubator at 37 ° C. to evaluate the activity of intestinal immune cells do. The cell activation value is shown in FIG. 2 by measuring OD (optical density) at 450 nm.

As can be seen in Fig. 2, the catechin increased 103% more of the intestinal immune activity than the negative control that did nothing. When catechin and lactic acid bacteria were treated together, 103% of LP 1, 73% of LP 2, and 100% of LP 3, respectively, were compared with the negative control (control) 186% in the case of Lactobacillus paracasei, and 46% in the case of Lactobacillus laminocus. On the other hand, the 10 μg / ml LPS used as a positive control increased the intestinal immune activity by 179% compared to the negative control.

As described above, when lactic acid bacteria and catechin are treated together, it is confirmed that they exert greater intestinal immune activity than the case of treating alone with each other. Especially, when Lactobacillus paracasei and catechin are treated together, The activity is further increased. This was much more effective than the positive control, LPS. That is, when tea extracts containing lactic acid bacteria and catechin are used together, synergy is shown to increase the intestinal immune activity.

[Experimental Example 4] Evaluation of macrophage activity

The mouse macrophage cell line (Raw 264.7) is put into a sterile glass-slide chamber at 1 × 10 ³ cells / well and cultured in a 5% CO ₂ , 37 ° C. incubator for 48 hours. After culturing, the prepared lactic acid bacteria and catechin samples prepared in Experimental Example 3 were treated with macrophages and cultured for 48 hours. Then, the culture medium was removed, fixed with 10% formalin, and then examined for the shape and size of macrophages using an electron microscope . The degree of macrophage activation when Lactobacillus paracasei and catechin were treated together is shown in Fig. 3 as compared to the negative control.

As can be seen from Fig. 3, in the case of the negative control group in which nothing is processed, the macrophage maintains a round shape and the surface is not unfolded. However, when Lactobacillus paracase and catechin are treated together, macrophages are activated and resemble dendritic cells. Thus, tea extracts containing lactic acid bacteria and catechin can activate macrophages and increase immunity.

Hereinafter, formulation examples of the composition according to the present invention will be described in more detail. However, the composition can be applied to various formulations, and it is not intended to limit the present invention but to specifically describe it.

[Formulation Examples 1 to 3]

Constituent Formulation Example 1 Formulation Example 2 Formulation Example 3 Tea extract (mg) 100 2000 10000 Lactic acid bacteria (cfu) 10 ¹³ 10 ¹³ 10 ⁶ Dietary Fiber (mg) 1000 1000 3000 Stevioside (mg) 10 100 300 The oligosaccharide (mg) 3000 3000 3000 Citric acid (mg) 100 300 500 Grapefruit flavor (mg) 80 160 300 Fir Apple Extract (mg) 500 800 1500 Gum arabic (mg) 300 100 50

[Formulation Example 4] Health drinks

Tea extract ............ 1000 mg

Lactic acid bacteria ................... 1000 mg

Citric acid ................... 1000 mg

Oligosaccharides ................... 100 g

Taurine ....................... 1 g

Purified water was added to the whole to obtain 900 ml

The above ingredients are mixed according to a conventional health drink manufacturing method, and then heated with stirring at 85 캜 for about 1 hour. The resulting solution is filtered, sterilized in a sterilized 2 liter container, sterilized by sealing, and stored in a refrigerator for use in manufacturing a health beverage composition of the present invention.

[Formulation Example 5] Powder

Tea extract ......................... 100 mg

Lactic acid bacteria ............................ 100 mg

Lactose .............................. 100 mg

Talc ............................... 10 mg

Maintenance ................................. 5 mg

The above components are mixed and filled in airtight bags to prepare powders.

Korea Microorganism Conservation Center (Domestic) KCCM11179P 20110328 Korea Microorganism Conservation Center (Domestic) KCCM11181P 20110328

Claims (12)

A combination of catechin and lactic acid bacteria as active ingredients,
Wherein the lactic acid bacterium is Lactobacillus paracasei .
delete The method according to claim 1,
Wherein the catechin comprises at least one of epigallocatechin gallate, epigallocatechin, epicatechin gallate, and epicatechin.
The method according to claim 1,
Wherein the lactic acid bacterium is dead bacteria.
The method according to claim 1,
Wherein the concentration of the lactic acid bacteria is 10 < ⁵ > -10 < ¹³ >
The method according to claim 1,
Wherein the composition comprises 0.000005 wt.% To 45 wt.% Catechin and 0.1 wt.% To 20 wt.% Lactic acid bacteria relative to the total weight of the composition.
7. The method according to any one of claims 1 to 6,
Intestinal disorders include at least one of colon cancer, enteritis, intestinal ulcer, irritable bowel syndrome, diarrhea and constipation.
7. The method according to any one of claims 1 to 6,
Wherein the composition enhances intestinal immune function.
7. The method according to any one of claims 1 to 6,
The composition activates macrophages.
7. The method according to any one of claims 1 to 6,
Wherein the composition is a food composition.
7. The method according to any one of claims 1 to 6,
Wherein the composition is a pharmaceutical composition.
7. A process for the production of a composition according to any one of claims 1 to 6,
7. A method for producing a composition according to any one of claims 1 to 6, comprising the step of extracting tea fermented with lactic acid bacteria.

Images